Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. is poised for a favorable financial outlook due to the recent expansion of its Cortrophin sales force, which has significantly contributed to the product's success and enhanced revenue potential. The company is seeing positive trends in cortrophin prescriptions, supported by a data-driven approach that has improved its ability to engage with payers and secure script approvals. Additionally, this growth has led to an upward revision of revenue estimates for Cortrophin, indicating strong demand and the capacity for further financial investment in this area.

Bears say

ANI Pharmaceuticals operates in the competitive generic pharmaceuticals market, facing significant risks related to pricing pressures, reimbursement challenges, and manufacturing execution. The company's substantial debt load exceeding $600 million raises financial concerns, further compounded by potential reputational risks linked to its product categories. The presence of competitive threats adds to the uncertainty surrounding its market position, which could negatively impact future revenue and profitability.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.